Monday November 18, 2024

Trending

Thomson Reuters CEO: With Changes to U.S. policy likely, here’s what to expect for AI in business and government42 mins ago
Nvidia Stock Sinks On Blackwell AI Chip Overheating Concerns42 mins ago
Rankings show Colorado’s business climate is worsening, chamber says42 mins ago
Rolls-Royce is in talks to use its compact nuclear reactors to power data centers and space missions42 mins ago
3 High-Return Skills To Learn As A Business Owner In 202542 mins ago
Federal workers brace for Trump with morale ‘as low as it’s ever been’42 mins ago
The Agenda: Local government meetings this week42 mins ago
Analysis: What is impoundment? How Trump thinks he can control spending without Congress42 mins ago
Jewish Agency hails world Jewry for stepping in after Oct. 7 attacks, boosts ties with Druze community at Board of Governors meeting42 mins ago
Trump’s influence already generating drama among world leaders as G20 gets underway42 mins ago

We aim to provide comprehensive news coverage from trusted various sources worldwide. We help people to have a personalized and engaging news experience.

Tirzepatide improves heart health and function in obese HFpEF patients

By TRENDING HEALTHNov 18, 2024

Minute Read0Comment2View

In the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking tirzepatide for up to 3 years had a reduced combined risk of worsening heart failure events and cardiovascular death, and improved health status and physical function in comparison to participants taking placebo, according to late-breaking science presented today at the American Heart Association’s Scientific Sessions 2024.

Health